Navigation Links
BioMS Medical to present at BioCentury Conference
Date:3/24/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, March 24 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the BioCentury "Future Leaders in the Biotech Industry" Conference in New York.

WHEN: Thursday March 27th at 2:00pm (Eastern Time)

WHERE: The Millennium Broadway Hotel & Conference Center, New York

About BioCentury "Future Leaders in the Biotech Industry" Conference

-------------------------------------------------------------------- This conference offers senior investment professionals an opportunity to review investment opportunities: companies making the transition from the private to public equity markets, as well as public plays positioned to move between tiers based on value or milestones. For more information visit: http://www.biocentury.com/BCApp/BioCenturyCommon/BCConferences.aspx?ss=1

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical Announces 2007 Year End Results
2. BioMS Medical to present at BIO CEO & Investor Conference
3. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical announces third quarter 2007 results
7. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. BioMS Medical to present at BioContact 2007
10. BioMS Medical announces its intention to renew a normal course issuer bid
11. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... Yorba Linda, Ca (PRWEB) , ... May 25, 2017 , ... ... events for tech innovators, engineers, and scientists from around the world, is announcing a ... scholarship is open to both undergraduate and graduate students, 17 years or older, pursuing ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... selection and implementation of CLEARAS Water Recovery’s Advanced Biological Nutrient Recovery (ABNR™) technology ... component of a $24 million plant upgrade to sustainably meet current and future ...
(Date:5/24/2017)... (PRWEB) , ... May 23, 2017 , ... Federal funding ... well as an enabler of life-saving medical and other vital technologies — deserves continued ... They joined others in the scientific community today in responding to the President’s budget ...
(Date:5/24/2017)... Ebola resurfaces in the Democratic Republic of Congo ... reported, a new analysis of the Ebola gene polymerase Replikin ... 2014 and 2017 outbreaks of the disease.  ... the 2014 outbreak. An analysis of the latest data showed ... which again precedes the current outbreak in the DRC. Sequence ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):